Hi all,
The drug companies are temporarily suspending enrollment of new patients into clinical trials evaluating the new histone deacetylase inhibitor MGCD0103.
This voluntary precaution is being taken due to the observation of pericarditis or pericardial effusion (heart complications
) in 19 patients out of approximately 400 patients treated to date.
https://www.fiercebiotech.com/biotec...-into-mgcd0103
Kind regards
Birgitta-A